In a welcome move, Vertex Pharmaceuticals saw its Relative Strength Rating improve from 67 to 73 on Monday.
IBD's proprietary rating tracks price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best stocks often have an 80 or higher RS Rating as they launch their largest climbs. See if Vertex Pharmaceuticals can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Vertex Pharmaceuticals is building a consolidation with a 519.88 buy point. See if it can clear the breakout price in volume at least 40% above average.
Earnings growth declined last quarter from 7% to -5%, but the top line rose from 12% to 16%.
Vertex Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech is the top-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
